People: Axis Shield PLC (ASD.L)

ASD.L on London Stock Exchange

393.00GBp
4:17am EST
Price Change (% chg)

-7.00p (-1.75%)
Prev Close
400.00p
Open
400.75p
Day's High
400.75p
Day's Low
393.00p
Volume
924
Avg. Vol
7,573
52-wk High
452.00p
52-wk Low
277.50p

view people for:

Summary

Name Age Since Current Position
Keen, Nigel 61 Non-Executive Chairman of the Board
Gilham, Ian 2008 Chief Executive Officer, Executive Director
Sperzel, John President of Axis-Shield USA
Hermansen, Ronny 2007 Group Finance Director, Executive Director
Sundrehagen, Erling Chief Scientific Officer, Executive Director
Gillies, Malcolm Company Secretary
Schjott, Atle Managing Director, Medinor Group
Shaw, Martin Managing Director, Plasmatec Laboratory Products Ltd
Schilling, Guido 2008 Managing Director, Axis-Shield AG Switzerland
Zajicek, George Business Development Director
Schmidt, Ralf Site Director, Point-of-Care Division
King, Colin Site Director, Laboratory Division
Richards, Simon 2009 Group Director Quality Assurance and Regulatory Affairs
Grimsrud, Kjersti Commercial Director, Point-of-Care Division
Green, M. 65 2009 Non-Executive Independent Director
Ek, Staffan 2006 Non-Executive Independent Director
Brown, John 54 2009 Senior Independent Non-Executive Director
» Insider Trading

Biographies

Name Description
Keen, Nigel Mr. Nigel Keen is Non-Executive Chairman of the Board of Axis Shield PLC in 1998. He has extensive experience of the bio-tech sector and is also Chairman of Laird plc, Oxford Instruments plc and Deltex Medical Group plc as well as a non-executive director of Bioquell plc. Nigel is the Chairman of the Compensation and Nomination Committees of Axis-Shield.
Gilham, Ian Mr. Ian Gilham, BSc, PhD, is Chief Executive Officer, Executive Director of Axis Shield PLC. Ian joined the Board of Axis-Shield in November 2001 from GlaxoSmithKline (GSK), where he held the position of Vice President – Pharmacogenetics. At GSK, he was responsible for the delivery of pharmacogenetic tests, as well as novel diagnostic tests used in targeting GSK’s medicines. Prior to joining GSK, Ian held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics. In January 2007 Ian was appointed Chief Operating Officer and was promoted to Chief Executive Officer in January 2008.
Sperzel, John Mr. John Sperzel, BSc, is President of Axis-Shield USA. John has a Bachelor of Science degree from Plymouth State College (Plymouth, NH). He has worked in the diagnostics industry for 20 years at Roche (Boehringer Mannheim), Instrumentation Laboratory and Bayer HealthCare. He joined Axis-Shield in 2004 from Bayer Diagnostics, where he was Vice President of Worldwide Marketing and Business Development for Near Patient Testing. John is based in Massachusetts where he is responsible for Axis-Shield in the USA.
Hermansen, Ronny Mr. Ronny Hermansen, MSc, is Group Finance Director, Executive Director of Axis Shield PLC on 1 April 2007. Ronny has a Master of Science degree in business (CandMerc) from the University of Aalborg in Denmark. He was the Finance Director for Axis Biochemicals ASA prior to its merger with Shield Diagnostics in 1999, and in that role he was responsible for the finance, administrative and IT functions of the Group’s Oslo operations. Previously, Ronny accumulated finance experience in the Norwegian pharmaceutical industry, most recently as Vice President Finance (Operations) at Nycomed Amersham.
Sundrehagen, Erling Dr. Erling Sundrehagen, MD, MSc, PhD, is Chief Scientific Officer, Executive Director of Axis Shield PLC. Erling is a medical doctor, a Master of Science in nuclear chemistry and has a PhD in immunology. Erling founded Axis Biochemicals ASA in 1985 and was appointed to the Board of Axis-Shield when Axis Biochemicals ASA merged with Shield Diagnostics in 1999. Erling has over 30 years’ experience within clinical chemistry and biochemistry. He has received various international awards for his research in clinical chemistry and is experienced in international patenting.
Gillies, Malcolm
Schjott, Atle Mr. Atle Schjott, BA, is Managing Director, Medinor Group of Axis Shield PLC. Atle has a Business Administration degree (Siviløkonom) from the University of Lund. He has held various positions, including controlling, marketing and administration within medical, pharmaceutical, dental and laboratory supply companies in Norway. He joined Medinor in 1996.
Shaw, Martin Mr. Martin Shaw, BSc, is Managing Director of Plasmatec Laboratory Products Ltd. Martin has a BSc from the University of Wales. He founded Plasmatec Laboratory Products Ltd in 1990 and has worked for the Axis-Shield Group since its acquisition of Plasmatec in 1996. Martin has over 20 years’ experience in the IVD industry specialising in international trade and marketing. Martin was appointed Managing Director of Plasmatec Laboratory Products Ltd in 1999.
Schilling, Guido Mr. Guido Schilling is Managing Director, Axis-Shield AG Switzerland since January 2008. Guido has worked in the pharmaceutical and diagnostic industry for over 30 years. He holds a Swiss Federal Diploma in Marketing and Sales Management obtained at the University of St Gallen. Guido has held various positions in national and international management, mainly within pharmaceutical companies. He joined Nycomed AG Switzerland in 1993 as Marketing Manager, responsible for the pharmaceutical and diagnostic product portfolio.
Zajicek, George Mr. George Zajicek, BPharm, MRPharmS, FTOPRA, is Business Development Director of Axis Shield PLC. George is a pharmacist who previously worked for Unipath Limited and Boehringer Ingelheim. George is a founder member and ex-chairman of the UK In Vitro Diagnostics (IVD) Industry Trade Association, BIVDA, and a prominent figure in the European IVD industry. George joined the Group in 1989. He is charged with developing new business for Axis-Shield, particularly for OEM contracts with multinational organisations.
Schmidt, Ralf Mr. Ralf Schmidt, Dipl Ing, MSc, DSc, is Site Director, Point-of-Care Division of Axis Shield PLC. Ralf qualified as Diplom Ingenieur (Chemical Technique/Process) from the University of Stuttgart. He has an MSc in Chemical Engineering from the University of Wisconsin and is a DSc from the Chemical Institute of the University of Oslo. He started his working life in 1992 as a scientist in the oil and gas sector, progressing to senior engineer and then technical chief within Norsk Hydro Aluminium, Germany. After a short spell in management consultancy, he joined Dynal Biotech (later acquired by Invitrogen) as VP, Operations. He joined the Axis-Shield Group in May 2006.
King, Colin Mr. Colin King is Site Director, Laboratory Division of Axis Shield PLC. Colin has a business administration degree from the University of Abertay. He has 15 years’ experience in operations management and has coordinated a number of large profile projects. Colin is an example of Axis-Shield’s succession planning, having joined Axis-Shield 12 years ago. He has held various positions within the Laboratory Division’s management team culminating in his promotion during 2007 to site director.
Richards, Simon Mr. Simon Richards, PhD, is Group Director Quality Assurance and Regulatory Affairs of Axis Shield PLC. Simon has a PhD from the University of Wales, Cardiff. Following three years’ postdoctoral work in arthritis research, he has worked in the IVD and vaccine industry for over 18 years. Simon worked at Amersham International, Johnson and Johnson, DPC and Chiron/Novartis before joining Axis- Shield in January 2008. Previous positions encompassed a variety of quality assurance, quality improvement and regulatory affairs roles at increasing levels of seniority. He is also a Six-Sigma Black Belt. In March 2009 he was appointed as Group Director QA/RA. Simon is based in Dundee where he is responsible for Quality Assurance.
Grimsrud, Kjersti Ms. Kjersti Grimsrud, MSc, is Commercial Director, Point-of-Care Division of Axis Shield PLC. Kjersti has an MSc in Biotechnology and has been with the Group for 22 years (since Axis Biochemicals was established in Norway). Over that time Kjersti has held various positions, including research scientist, product manager, area manager, and marketing director. As Commercial Director of the PoC Division.
Green, M. Mr. M.J. Green, FCA, MSI, is Non-Executive Independent Director of Axis Shield PLC since March 2005. He has over 30 years’ experience in corporate finance and is currently Vice Chairman of Dresdner Kleinwort. Bay is the senior independent non-executive director of RPC Group plc, Chairman of its Audit Committee and a member of its Remuneration and Nomination Committees. Bay is also a non-executive director of Invensys plc, Chairman of its Audit Committee and a member of the Remuneration and Nominating Committees. Bay is Chairman of the Audit Committee and a member of the Compensation and Nomination Committees of Axis-Shield. He is also a specialist advisor to the Institutional and Wholesale Markets Division of the Financial Services Authority.
Ek, Staffan Mr. Staffan Ek, BSc, is Non-Executive Independent Director of Axis Shield PLC since March 2006. He has extensive knowledge of the healthcare sector, acquired over thirty years in the industry, primarily with Pharmacia, Boehringer Mannheim and Roche Diagnostics. Staffan retired from Roche at the end of 2005, where he was President of Diabetes Care, an Executive Director of Roche Diagnostics, and a permanent participant of the Corporate Executive Committee of F Hoffmann-La Roche AG, Basle, Switzerland. Staffan is a non-executive director of Facet Technologies LLC, Atlanta, USA and DAKO A/S, Glostrup, Denmark. Staffan serves on the Audit and Compensation Committees of Axis-Shield.
Brown, John Dr. John Brown, PhD MBA FRSE, is Senior Independent Non-Executive Director of Axis Shield PLC in March 2009. He has extensive experience in the life sciences sector. He is Chairman of BTG plc and CXR Biosciences Ltd and a non-executive director of Vectura Group plc, and was a Director of Cambridge Antibody Technology plc until its acquisition by AstraZeneca. In the public sector he chairs the Roslin Foundation and the Life Sciences Industry Advisory Board and is a non-executive director of the Technology Strategy Board. He is an advisor to several private equity and venture capital funds, a Fellow of the Royal Society of Edinburgh and Honorary Professor of the University of Edinburgh. Until December 2003, John was Chief Executive of Acambis plc, a producer of vaccines to treat and prevent infectious disease. He joined Acambis as Finance Director in 1995 and was appointed CEO in 1997.

Insider Trading

» Full list on Insider Trading
view people for: